Conclusion: The HBV
preS/
S C-terminal truncation mutant
sW196*, which may be selected in NA (3TC, Telbivudine, or Entecavir)-resistant
rtM204I strains, potentially confers cell transformation and tumorigenesis ability through altered (up- or down-regulated) cellular transcriptions that orchestrate in different cancer-promoting sectors.